24486-40-6

Usage

Uses

Tetramet (Abbott).

Upstream product

• 534-51-0 3,5-diiodo-DL-thyronine 
• 300-39-0 3,5-diiodo-l-tyrosine 
• 1041-01-6 3,5-diiodo-L-thyronine 
• 968-21-8 H-Leu-Tyr-OH 
• 7553-56-2 iodine 
• 300-30-1 thyroxine 
• 16711-71-0 D-3,5-Diiodotyrosine 
• 5563-89-3 D-Diiodothyronine 
• 556-02-5 tyrosine 
• 502481-40-5 N-acetyl-3,5-diamino-O'-methyl-D-thyronine ethyl ester 
• 502481-41-6 N-acetyl-3,5-diiodo-O'-methyl-D-thyronine ethyl ester 
• 120408-14-2 N-formyl-3,5-diiodo-D-thyronine 
• 94298-44-9 N-formyl-3,5-diiodo-DL-thyronine 
• 19231-06-2 4,4'-dimethoxy-diphenyliodonium bromide 

Downstream Products

• 1396518-43-6 2-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]acetaldehyde 
• 64192-57-0 3,3'-diiodo-L-thyronine sulfate 
• 31135-55-4 L-Triiodothyronine sulfate 
• 26041-51-0 (S)-2-acetamido-3-(4-(4-hydroxy-3,5-diaiodophenoxy)-3,5-diaiodophenyl)propanoic acid 
• 88404-22-2 (S)-2-((tert-butoxycarbonyl)amino)-3-(4-(4-hydroxy-3,5-diaiodophenoxy)-3,5-diaiodophenyl)propanoic acid 
• 1234572-95-2 oxiran-2-ylmethyl 2-(tert-butoxycarbonylamino)-3-(4-(3,5-diiodo-4-(oxiran-2-ylmethoxy)phenoxy)-3,5-diiodophenyl)propanoate 
• 1234572-96-3 triisopropylsilyl 2-(tert-butoxycarbonylamino)-3-(4-(3,5-diiodo-4-(oxiran-2-ylmethoxy)phenoxy)-3,5-diiodophenyl)propanoate 
• 1234572-94-1 triisopropylsilyl 2-(tert-butoxycarbonylamino)-3-(4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl)propanoate 
• 2278-95-7 4-(4-hydroxy-3,5-diiodo-phenoxy)-3,5-diiodo-trans-cinnamic acid 
• 2389-84-6 4-(4-hydroxy-phenoxy)-3,5-diiodo-trans-cinnamic acid 
• 101096-70-2 3-amino-3-[4-(4-hydroxy-phenoxy)-3,5-diiodo-phenyl]-propionic acid 

Relevant academic research and scientific papers

Improved method for synthesizing L-thyroxine sodium

The invention relates to an improved method for synthesizing L-thyroxine sodium. The improved method includes the steps that 3,5-diiodomethane-L-tyrosine is used as a raw material, and then subjectedto a copper complex reaction, a coupling reaction, an acid hydrolysis reaction, an iodine generation reaction and a salt forming reaction to obtained the L-thyroxine sodium. According to the improvedmethod for synthesizing the L-thyroxine sodium, the yield of the L-thyroxine sodium can be improved, the product cost is lowered, and industrialization is convenient.

Liquid levothyroxine formulations

Embodiments of the present invention provide levothyroxine solutions that consist of from about 0.001% w/v to about 0.01% w/v of a levothyroxine; at least 70% w/w of a glycerol; less than 30% w/w of a water; and from about 0.01% w/w to about 1.5% w/w of an ethylenediaminetetraacetic acid (EDTA). Such levothyroxine solutions are characterized by exhibiting levothyroxine storage stability.

A PROCESS FOR PREPARATION OF LEVOTHYROXINE AND SALTS THEREOF

The present invention relates to a process for the preparation of Levothyroxine and salts thereof. The process described in the present invention provides increase in the yields and purity comprising the use of sodium iodide and sodium hypochlorite as iodinating agent.

NOVEL PROCESS FOR THE PREPARATION OF LEVOTHYROXINE SODIUM

The present invention provides a novel process for the preparation of highly pure Levothyroxine Sodium, i.e., (S)-2-amino-3-[4-(4-hydroxy-3, 5-diiodophenoxy)-3,5- diiodophenyl] propanoic acid sodium salt via two process intermediates viz 3,5-Diiodo L- Tyrosine copper complex and novel Bis (p-anisyl) iodonium lodide.The invention also provides levothyroxine pentahydrate free from genotoxic impurities and liothyronine levels below 0.04% wt/wt.

The synthesis of 13C9-15N-labeled 3,5-diiodothyronine and thyroxine

Thyroid hormones undergo extensive metabolism to regulate hormone activity. A labeled thyroid hormone would be useful to track hormone metabolism through various pathways. While radiolabeled thyroid hormones have been synthesized and used for in vivo studies, a stable isotope labeled form of thyroid hormone is required for studying thyroid hormone metabolism by LC-MS/MS, an analytical technique that has certain advantages without the complications of radioactivity. Here we report the synthesis of 13C9- 15N-T2 and 13C9-15N- T4, two labeled thyroid hormone derivatives suitable for in vivo LC-MS/MS studies. Supplemental materials are available for this article. Go to the publisher's online edition of Synthetic Communications to view the free supplemental file.

BIOTINYLATED THYROXINE

A means for conveniently and accurately measuring thyroxine or thyronine present in the blood or the like is provided: a compound represented by general formula (I) below: wherein L represents a linear or branched-chain linker having 5 to 50 total atoms; X represents one or more thyroxines, thyronines, or residues of derivatives thereof, bound to the main chain and/or side chain of the linker represented by L, a conjugate in the form of the above compound bonded to an avidin protein, and an aqueous dispersion including a microparticles the surface of which is modified with the above conjugate.

COMPOSITIONS AND METHODS FOR CYCLOFRUCTANS AS SEPARATION AGENTS

The present invention relates to derivatized cyclofructan compounds, compositions comprising derivatized cyclofructan compounds, and methods of using compositions comprising derivatized cyclofructan compounds for chromatographic separations of chemical species, including enantiomers. Said compositions may comprise a solid support and/or polymers comprising derivatized cyclofructan compounds.

AN IMPROVED PROCESS FOR THE PREPARATION OF LEVOTHYROXINE SODIUM WITH REDUCED LEVELS OF IMPURITIES

The invention relates to an improved process for the preparation of Levothyroxine sodium with reduced levels of impurities. The invention also provides Levothyroxine sodium pentahydrate free from 3,5-Diiodothyronine or d-enantiomer of thyroxine. The invention also provides Levothyroxine sodium pentahydrate having liothyronine below 0.5% wt / wt.

Enantioseparation using cyclosophoraoses as a novel chiral additive in capillary electrophoresis

Cyclosophoraoses, cyclic β-(1→2)-D-glucans produced by Rhizobium meliloti 2011, were used as a novel chiral additive for the separation of terbutaline, amethopterin, thyroxine and N-acetylphenylalanine enantiomers in aqueous capillary electrophoresis (CE). Enantioseparation took place in the normal- or reversed-polarity mode when a high concentration of neutral (60 mM) or anionic (40 mM) cyclosophoraoses was added to the background electrolyte (BGE).

Composition of matter having bioactive properties

Particles of coordinated complex comprising a basic, hydrous polymer and a capacitance adding compound, as well as methods for their production, are described. These complexes exhibit a high degree of bioactivity making them suitable for a broad range of applications through their incorporation into conventional vehicles benefiting from antimicrobial and similar properties.